Inventiva (IVA) has released an update.
Inventiva, a clinical-stage biopharmaceutical company, reported its total voting rights and share capital as of May 13, 2024, alongside updates on its clinical programs. The company’s primary focus is on lanifibranor, currently in a pivotal Phase III trial for MASH/NASH, a chronic liver disease lacking approved therapies. Inventiva is also reviewing development opportunities for its suspended drug candidate odiparcil and identifies candidates in its Hippo signaling pathway program.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
